Evidence map›Paper›PMID 25109331›Full record

ArticleOncogene2015

Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.

P Riemer, A Sreekumar, S Reinke, R Rad, R Schäfer, C Sers, H Bläker, B G Herrmann, M Morkel

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. BRAFiScience · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. BRAFCommunications biology · 2023
    Article
  9. Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.Virchows Archiv : an international journal of pathology · 2023
    Article
  10. Sensitivities and Dependencies ofMedicina (Kaunas, Lithuania) · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. BRAFOncogene · 2020
    Article
  16. Wnts and the hallmarks of cancer.Cancer metastasis reviews · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

P Riemer1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
A Sreekumar1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
S ReinkeDepartment of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
R Rad1] Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, München, Germany [2] German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
R Schäfer1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
C Sers1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
H BläkerDepartment of General Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
B G HerrmannDepartment of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
M Morkel1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEMax Planck Institute for Molecular Genetics · DEKlinikum rechts der Isar · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colon cancer cells frequently carry mutations that activate the β-catenin and mitogen-activated protein kinase (MAPK) signaling cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/β-catenin signals encourage ISC identity, we asked whether β-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3β. Similarly, transgenic expression of stabilized β-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We also used BRAF(V637E) knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker expression reduced in serrated hyperplasia forming after BRAF activation, but intensified in progressive dysplastic foci characterized by additional mutations that activate the Wnt/β-catenin pathway. Our study suggests that oncogenic alterations activating the MAPK and Wnt/β-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation.

Indexed as

Animalsbeta CateninCaco-2 CellsCarcinogenesisCell CountCell ProliferationColonic NeoplasmsGene ExpressionHumansIntestinal MucosaIntestinesMiceMice, Inbred C57BLMice, TransgenicProto-Oncogene Proteins B-rafStem Cellsbeta CateninBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID25109331
OpenAlexW2025321654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.